Biogen takes another blow as appeal for Tecfidera patent revival falls short | Fierce Pharma
Sole Challenger HEC Beaten On US Gilenya Patent :: Generics Bulletin
Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS - Bloomberg
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
Alembic Pharma gets USFDA approval for hypertension drug - Elets eHealth
/cloudfront-us-east-2.images.arcpublishing.com/reuters/4SADGYNDOJLEBHXQYSBDSEA5AI.jpg "Novartis loses in patent appeal over multiple sclerosis drug | Reuters")
Novartis loses in patent appeal over multiple sclerosis drug | Reuters
Novartis (NOVN) Wins U.S. Appeal Affirming Patent on MS Drug - Bloomberg
FDA greenlights generics of Novartis' $3B MS star Gilenya amid legal fight | Fierce Pharma
Gilead's $3B Truvada will face generics a year early. Can Descovy still win over its patients? | Fierce Pharma
Novartis' Gilenya staves off generic challengers—for now—after federal injunction | Fierce Pharma
FiercePharmaAsia—Takeda's workforce rejig and Velcade patent win, China's insurance drug list | Fierce Pharma
Biogen Suffers Yet Another Setback as an Appeal for the Tecfidera Patent is Denied. | News & Updates
Bristol Myers Squibb's Zeposia launches into crowded MS market | Fierce Pharma
Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic) - Not-so-Hidden Gems - ValuePickr Forum
It's confirmed: Amarin loses Vascepa patent appeal, putting generics defense on life support | Fierce Pharma
Roche says hola to Hispanic, Latinx multiple sclerosis communities | Fierce Pharma
Lilly fends off Cialis generics with new patent settlement | Fierce Pharma
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court | Fierce Pharma
Novartis wins Supreme Court temporary reprieve on Gilenya generics (NYSE:NVS) | Seeking Alpha
/cloudfront-us-east-2.images.arcpublishing.com/reuters/S2ZVV3DI4ZIZHAUZZLLFYCSR6Y.jpg "U.S. Supreme Court grants Novartis request to halt Gilenya generic rivals | Reuters")
U.S. Supreme Court grants Novartis request to halt Gilenya generic rivals | Reuters
Novartis loses appeal for patent on multiple sclerosis drug (NYSE:NVS) | Seeking Alpha
Riding on patent office win, Novartis takes Gilenya generics fight to court | Fierce Pharma
natco: Patent infringement lawsuit filed against Natco by Johnson & Johnson, Momenta - The Economic Times
